With Claimed Perfecting Feature In Contents (e.g., Excipient, Lubricant, Etc.) Patents (Class 424/465)
  • Extended release composition comprising as active compound venlafaxine hydrochloride
    Publication number: 20030190354
    Abstract: A composition suitable for use in making extended release tablets of venlafaxine hydrochloride is described.
    Type: Application
    Filed: April 3, 2003
    Publication date: October 9, 2003
    Inventor: Yoram Sela
  • Extended release venlafaxine formulations
    Publication number: 20030190351
    Abstract: A pharmaceutical composition is provided comprising venlafaxine hydrochloride and sodium carboxymethyl cellulose. The composition can be formulated to provide controlled release of the venlafaxine hydrochloride.
    Type: Application
    Filed: March 27, 2003
    Publication date: October 9, 2003
    Applicant: Synthon BV
    Inventors: Johannes Jan Platteeuw, Inocencia Margallo Lana, Arturo Siles Ortega
  • Methods of stabilizing pharmaceutical compositions
    Publication number: 20030190349
    Abstract: The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as levothyroxine (T4) sodium and liothyronine (T3) sodium (thyroid hormone drugs), preferably in an immediate release solid dosage form. Also provided are methods for making and using such immediate release and stabilized compositions.
    Type: Application
    Filed: August 10, 2002
    Publication date: October 9, 2003
    Inventors: G. Andrew Franz, Elaine A. Strauss, Phillip A. DiMenna, Rocco L. Gemma
  • Compositions of venlafaxine base
    Publication number: 20030190352
    Abstract: Solid venlafaxine base can be advantageously employed in making pharmaceutical compositions, especially extended release compositions.
    Type: Application
    Filed: March 27, 2003
    Publication date: October 9, 2003
    Applicant: SYNTHON BV
    Inventors: Juan Cucala Escoi, Montserrat Gallego Luengo, Marinus J. M. Oosterbaan, Frantisek Picha
  • Spheronized self-emulsifying system for hydrophobic and water-sensitive agents
    Patent number: 6630150
    Abstract: A self-emulsifying system comprises i) microcrystalline cellulose and ii) an oily substance, surfactant, and water is useful for providing solid dosage forms of hydrophobic or water sensitive agents when dried or extruded and spheronized.
    Type: Grant
    Filed: October 15, 2001
    Date of Patent: October 7, 2003
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Steven William Booth, Ashley Clarke, John Michael Newton
  • Process for the preparation of rapidly disintegrating tablet
    Publication number: 20030185886
    Abstract: The present invention relates to a process for the preparation of a tablet having an enhanced strength as well as a high disintegrating rate in the oral cavity, which comprises: spray-drying an active ingredient to obtain a spray-dried particulate containing the active ingredient; mixing the spray-dried particulate, a sublimable substance suitable for oral administration, a poly(ethylene glycol), and a pharmaceutically acceptable additive; tableting the mixture; and drying the resulting tablet to sublime the sublimable substance until the tablet becomes porous.
    Type: Application
    Filed: March 17, 2003
    Publication date: October 2, 2003
    Applicant: Hanmi Pharm. Co., Ltd.
    Inventors: Chang-Hyun Lee, Jong-Soo Woo, Hee-Chul Chang
  • Glyburidge composition
    Publication number: 20030185880
    Abstract: The present invention relates to a physical form of the known drug substance glyburide, also known as glibenclarnide, and chemically defined as 5-chloro-N-[2-[4-[[[(cyclohexylamino)-carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxybenzamide (Merck Index, Tenth Edition, p. 642), as well as to dosage forms, e.g., tablets and capsules, incorporating said physical form of glyburide.
    Type: Application
    Filed: April 30, 2003
    Publication date: October 2, 2003
    Inventors: Gillian Cave, Sarah J. Nicholson
  • Therapeutic agent delivery compositions for buccal cavity absorption of pilocarpine
    Publication number: 20030185884
    Abstract: A therapeutic agent delivery composition containing a functional buffer system for facilitating absorption of pilocarpine in the buccal cavity. More particularly, the composition is used to raise the pH of the buccal cavity so that the pilocarpine agent is delivered in a lipophilic form capable of crossing the buccal membrane. The delivery composition raises the pH of the buccal cavity through the implementation of a buffer system, which comprises a combination of two or more buffer agents. The agents of the buffer system are combined in a manner where the stronger basic agent is at relatively larger levels than that of a corresponding weaker base. The delivery composition may be administered as a chewing gum, where the pilocarpine is effectively absorbed in about 5 minutes after the onset of chewing.
    Type: Application
    Filed: April 1, 2002
    Publication date: October 2, 2003
    Inventors: Nikhilesh Nihala Singh, Natasha Nikhilesh Singh
  • Non-granulated levothyroxine pharmaceutical compositions
    Publication number: 20030185885
    Abstract: The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as levothyroxine (T4) sodium and liothyronine (T3) sodium (thyroid hormone drugs), preferably in an immediate release solid dosage form. Also provided are methods for making and using such immediate release and stabilized compositions.
    Type: Application
    Filed: August 10, 2002
    Publication date: October 2, 2003
    Inventors: G. Andrew Franz, Elaine A. Strauss, Phillip A. DiMenna, Rocco L. Gemma
  • Methods of treatment and formulations of cephalosporin
    Publication number: 20030186957
    Abstract: Formulations containing an antibacterial alkali metal salt of a cephalosporin compound and methods of treating bacterial infections in dogs and cats.
    Type: Application
    Filed: November 12, 2002
    Publication date: October 2, 2003
    Inventors: Simon E. Blanchflower, Roger N. Kimball, Renuka D. Reddy, Evgenyi Y. Shalaev, Brian S. Bronk
  • Appetite suppressant for oral ingestion
    Publication number: 20030185883
    Abstract: A method of suppressing human appetite, and a material therefore, are disclosed in the claims. The method includes the step of inducing body weight loss in a human by providing that human with material containing, as an active ingredient, 2-AcetylPyridine for human oral consumption. The material can be provided in the form of a lozenge. A related aspect of the invention relates to material for human ingestion to encourage body weight loss, the material comprising about 1% 2-AcetylPyridine volume/volume.
    Type: Application
    Filed: March 28, 2002
    Publication date: October 2, 2003
    Inventor: Ronald S. Nietupski
  • Water dispersible formulation of paroxetine
    Publication number: 20030186938
    Abstract: A water-dispersible formulation of paroxetine for immediate oral administration comprises a dry blend of paroxetine, a water-soluble dispersing agent, and a taste-masking agent, as a dispersible powder or moulded into a tablet.
    Type: Application
    Filed: June 9, 2003
    Publication date: October 2, 2003
    Inventors: Ahmad Khalef Al-Deeb Al-Ghazawi, David Philip Elder, Padma Meneaud
  • Pharmaceutical compositions containing oxybutynin
    Publication number: 20030185882
    Abstract: A pharmaceutical composition and dosage form for the treatment of incontinence with oxybutynin and a second drug is provided. The second drug can be darifenacin or tolterodine. Depending upon the route of administration, the dosage form used, and the second drug used, the dosage form may independently include therapeutic or sub-therapeutic amounts of the oxybutynin and the second drug. Particular embodiments include a dosage form that provides a controlled release of oxybutynin and the second drug to maintain therapeutically effective levels oxybutynin and/or the second in a mammal for an extended period of time. An osmotic device containing a bi-layered core is provided. The osmotic device provides a dual controlled release of both drugs from the core. A method of treating urinary (stress or urge) incontinence with the pharmaceutical composition and dosage form is provided.
    Type: Application
    Filed: November 6, 2001
    Publication date: October 2, 2003
    Inventors: Juan A. Vergez, Marcelo A. Ricci
  • Amoxicillin-dicloxacillin antibiotic composition
    Patent number: 6627222
    Abstract: An antibiotic product for delivering at least Amoxicillin or dicloxacillin that is comprised of three dosage forms with different release profiles with each of Amoxicillin and dicloxacillin being present in at least one of the dosage forms.
    Type: Grant
    Filed: March 7, 2002
    Date of Patent: September 30, 2003
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbiter, Donald J. Treacy, Jr., Sandra E. Wassink
  • Stabilized thyroxine compounds
    Patent number: 6627660
    Abstract: Throxinyldimethylphosphinate was invented as a prodrug to stabilize thyroxine, a drug widely used to treat hypothyroidism. The presence of the dimethylphosphinate group at the phenolic hydroxyl of thyroxine is key to preventing thyroxine from decomposing through the proposed pathway. The prodrug will be hydrolyzed in the stomach or the gut into thyroxine and the biologically inert dimethylphosphinic acid. Related products may be stabilized with the same or similar protecting groups.
    Type: Grant
    Filed: November 16, 1999
    Date of Patent: September 30, 2003
    Assignee: New River Pharmaceuticals Inc.
    Inventors: Thomas Piccariello, Anne F. LeClercq
  • Polymeric delivery agents and delivery agents compounds
    Patent number: 6627228
    Abstract: Polymeric delivery agents, delivery agent compounds and compositions comprising them which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: September 30, 2003
    Assignee: Emisphere Technologies, Inc.
    Inventors: Sam J. Milstein, Eugene N. Barantsevitch, Nai Fang Wang, Jun Liao, John E. Smart, Richard D. Conticello, Raphael M. Ottenbrite
  • Pharmaceutical composition containing diphosphonic acid or salt thereof
    Patent number: 6627221
    Abstract: The invention relates to a solid pharmaceutical form of administration containing a diphosphonic acid or a physiologically compatible salt thereof as the active substance, wherein the active substance is present in granulate form, optionally together with pharmaceutical adjuvants in the inner phase, and the outer phase contains a lubricant in the form of less than 5% by weight of stearic acid relative to the total weight of the form of administration.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: September 30, 2003
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Rolf-Dieter Gabel, Walter Preis, Heinrich Woog
  • Tablets containing heat sensitive materials and method for forming thereof
    Patent number: 6627220
    Abstract: The present invention provides a process and apparatus for preserving the potency of a tableted heat sensitive ingredient. The process includes the steps of forming the ingredient into a tablet and cooling the tablet for a sufficient time and at a sufficiently low temperature to decrease the heat degradation of the ingredient. The process may be carried out in any number of tablet cooling apparatus, including a conduit forming a passageway for receiving tablets from the tablet press. A coolant inlet is connected to the conduit for supplying coolant into the passageway and into contact with the tablets.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: September 30, 2003
    Assignee: Scolr, Inc.
    Inventors: Stephen J. Turner, Steven K. Kazemi, Tanya M. Borek, Jeffrey S. White
  • Pharmaceutical tablet
    Publication number: 20030180357
    Abstract: A pharmaceutical tablet is provided comprising a core and a coating adherent thereto, wherein (a) the core comprises solid particles of a water-soluble dye distributed in a matrix, and (b) the coating comprises gellan gum. The tablet is suitable for peroral or intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject. The tablet has a speckled appearance that renders the tablet readily identifiable.
    Type: Application
    Filed: February 6, 2003
    Publication date: September 25, 2003
    Inventors: Alice C. Martino, Robert M. Noack, Steven A. Pierman
  • Amlodipine maleate formulations
    Publication number: 20030180354
    Abstract: The present invention relates to the stable solid orally administrable pharmaceutical formulation of Amlodipine Maleate. The invention also describes the process of producing such stable formulations and more specifically a direct compression method of producing tablet formulations. The tablet formulation of Amlodipine Maleate thus prepared is bioequivalent to the tablets containing Amlodipine Besylate salt commercially available with the brand name of Norvasc. The formulation also avoids the common problem of sticking observed during manufacturing.
    Type: Application
    Filed: September 13, 2002
    Publication date: September 25, 2003
    Applicant: DR. REDDY'S LABORATORIES LIMITED
    Inventors: Dinesh Dayaramji Chakole, Pallempalli Venkata Siva Reddy, Billa Praveen Reddy, Vipin Tatyasaheb Dhanorkar, Mailatur Sivaraman Mohan
  • Levothyroxine compositions having unique triiodothyronine Tmax properties
    Publication number: 20030180356
    Abstract: The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as levothyroxine (T4) sodium and liothyronine (T3) sodium (thyroid hormone drugs), preferably in an immediate release solid dosage form. Also provided are methods for making and using such immediate release and stabilized compositions.
    Type: Application
    Filed: October 29, 2002
    Publication date: September 25, 2003
    Inventors: G. Andrew Franz, Elaine A. Strauss, Philip A. DiMenna, Rocco L. Gemma
  • Intraorally disintegrating valdecoxib compositions
    Publication number: 20030181501
    Abstract: Orally disintegrating valdecoxib fast-melt tablets and processes for preparing such dosage forms are provided.
    Type: Application
    Filed: September 23, 2002
    Publication date: September 25, 2003
    Inventors: Trang T. Le, Blake C. Ludwig, Joseph P. Reo, Uday J. Shah, Ken Yamamoto
  • Stabilized pharmaceutical compositions
    Publication number: 20030180353
    Abstract: The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as levothyroxine (T4) sodium and liothyronine (T3) sodium (thyroid hormone drugs), preferably in an immediate release solid dosage form. Also provided are methods for making and using such immediate release and stabilized compositions.
    Type: Application
    Filed: August 10, 2002
    Publication date: September 25, 2003
    Inventors: G. Andrew Franz, Elaine A. Strauss, Phillip A. DiMenna, Rocco L. Gemma
  • Combination therapy for hypertension
    Publication number: 20030180355
    Abstract: Disclosed are compositions and methods for treating hypertension comprising enalapril and lercanidipine in amounts effective in combination to reduce blood pressure to a patent in need of treatment.
    Type: Application
    Filed: October 16, 2002
    Publication date: September 25, 2003
    Inventors: Amedeo Leonardi, Abraham Sartani, Giorgio Sironi
  • Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
    Publication number: 20030180352
    Abstract: The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides, and solubilizers. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides, and solubilizers. The compositions of the present invention can be used for improved delivery of active ingredients.
    Type: Application
    Filed: May 30, 2002
    Publication date: September 25, 2003
    Inventors: Mahesh V. Patel, Feng-Jing Chen
  • Dosage form of N-acetyl cysteine
    Patent number: 6623754
    Abstract: A directly-compressed, controlled release tablet contains N-acetyl cysteine as the active ingredient.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: September 23, 2003
    Assignee: Noveon IP Holdings Corp.
    Inventors: Jian-Hwa Guo, William Robert Wilber
  • Directly compressed solid dosage articles
    Patent number: 6623756
    Abstract: Solid dosage articles such as pharmaceutical tablets for the controlled release of a desired compound such as an active ingredient are directly compressed from a flowable, compressible mixture of the active ingredient, a slightly cross-linked rheology modifying polymer or copolymer, and one or more excipients. The rheology modifying polymer or copolymer is a granulated powder of suitable particle size and is generally made from one or more unsaturated (di)carboxylic acids, half ester thereof, and other optional monomers.
    Type: Grant
    Filed: April 27, 2000
    Date of Patent: September 23, 2003
    Assignee: Noveon IP Holdings Corp.
    Inventors: William R. Wilber, Jian-Hwa Guo, Edward S. Greenberg
  • Antibiotic composition
    Patent number: 6623757
    Abstract: An antibiotic product for delivering at least two different antibiotics that is comprised of three dosage forms with different release profiles with each antibiotic being present in at least one of the dosage forms.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: September 23, 2003
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Levothyroxine compositions having unique triiodothyronine Tmax properties
    Publication number: 20030175337
    Abstract: The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as levothyroxine (T4) sodium and liothyronine (T3) sodium (thyroid hormone drugs), preferably in an immediate release solid dosage form. Also provided are methods for making and using such immediate release and stabilized compositions.
    Type: Application
    Filed: October 29, 2002
    Publication date: September 18, 2003
    Inventors: G. Andrew Franz, Elaine A. Strauss, Philip A. DiMenna, Rocco L. Gemma
  • Process for preparing a soft tablet
    Publication number: 20030175339
    Abstract: The invention relates to a process for preparing a soft tablet capable of being chewed or disintegrated in the oral cavity. The tablet is prepared by forming a tablet having a friability of less than about 2% from a mixture comprising a pharmaceutically active ingredient, an excipient in the form of a hydrate, and a water-swellable excipient, and then applying sufficient energy, preferably in the form of heat, to the tablet for a sufficient time to decrease the hardness of the tablet by at least about 20%.
    Type: Application
    Filed: April 15, 2003
    Publication date: September 18, 2003
    Inventors: Frank J. Bunick, Joseph Luber
  • Soft tablet containing high molecular weight polyethylene oxide
    Publication number: 20030175336
    Abstract: The invention relates to an immediate release tablet capable of being chewed or disintegrated in the oral cavity, which comprises a pharmaceutically active ingredient, and a matrix comprising polyethylene oxide having a weight average molecular weight of from about 500,000 to about 10,000,000. The tablet possesses exceptionally good mouthfeel and stability.
    Type: Application
    Filed: March 13, 2002
    Publication date: September 18, 2003
    Inventors: Joseph Luber, Frank J. Bunick
  • Formulations of atorvastatin stabilized with alkali metal additions
    Publication number: 20030175338
    Abstract: A pharmaceutical formulation having improved bioavailability and bioequivalence includes particles of amorphous and/or crystalline atorvastatin that have a particle size (d90) less than 150 &mgr;m and a mean particle size (d50) of the atorvastatin particles that is between approximately 5 and 50 &mgr;m. The atorvastatin can be one or more of atorvastatin calcium, atorvastatin magnesium, atorvastatin aluminum, atorvastatin iron, and atorvastatin zinc. The formulations of atorvastatin can be stabilized by mixing atorvastatin with an alkali metal salt additive at between approximately 1.2% and less than 5% w/w of the formulation.
    Type: Application
    Filed: February 14, 2003
    Publication date: September 18, 2003
    Inventors: Romi Barat Singh, Pananchukunnath Manoj Kumar, Rajiv Malik
  • Edible compositions containing trehalose
    Patent number: 6620791
    Abstract: The invention provides edible compositions such as solid particulate sweeteners, boiled sweets, chocolate and chewing gum, wherein the compositions comprise at least 10% on a dry weight basis of one or more substances having an endothermic heat of solution of at least −30 kJ/kg and at least 10% on a dry weight basis of a substantially amorphous solid trehalose. The one or more substances having an endothermic heat of solution may comprise dextrose monohydrate or a crystalline sugar alcohol. The invention also provides processes suitable for the production of such edible compositions, wherein the processes comprise the step of dry mixing amorphous trehalose particles in an amount of at least 10% based on the dry weight of the composition with one or more other edible ingredients to form a dry mixture.
    Type: Grant
    Filed: April 16, 2002
    Date of Patent: September 16, 2003
    Assignee: British Sugar PLC
    Inventors: Julian Michael Cooper, Wei Tian
  • Dispersible and soluble galenic paracetamol formulation, method for its preparation and its applications
    Patent number: 6620433
    Abstract: The new galenic formulation of paracetamol is comprised of a base mixture of paracetamol and citric acid in a proportion of 85:15 to 90:10 w/w among other pharmaceutically acceptable components, in an exsiccation state corresponding to a water activity of less than 0.6 and it is in the form of a powder, granulate or tablet. The process comprises obtaining said exsiccated base mixture up to a water activity of less than 0.6 in order to obtain a powder, that can be granulated in order to obtain a granulate dispersible and soluble in water, whose granulate can also be compressed in order to obtain a tablet dispersible and soluble in water. Said new formulation is useful in human and veterinary medicine.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: September 16, 2003
    Assignee: Laboratorios Belmac, S.A.
    Inventors: Luis Carvajal Martín, Juan Carlos Asensio Asensio, Francisco Javier Sevilla Tirado
  • Sustained release ranolazine formulations
    Patent number: 6620814
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: September 16, 2003
    Assignee: CV Therapeutics, Inc.
    Inventors: Andrew A. Wolff, Fiona Baker, John Langridge
  • Pharmaceutical compositions comprising fluvastatin
    Publication number: 20030171419
    Abstract: Pharmaceutical compositions comprising fluvastatin, HPMC and optionally other pharmaceutical excipients which are colour-stable upon prolonged periods of storage.
    Type: Application
    Filed: October 15, 2002
    Publication date: September 11, 2003
    Inventors: Oskar Kalb, Stephen Valazza
  • Sustained release ranolazine formulations
    Patent number: 6617328
    Abstract: A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: September 9, 2003
    Assignees: CV Therapeutics, Inc, Syntex (USA), LLC
    Inventors: Andrew A. Wolff, Fiona Baker, John Langridge
  • Directly compressible formulations of azithromycin
    Publication number: 20030165563
    Abstract: The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient.
    Type: Application
    Filed: December 20, 2002
    Publication date: September 4, 2003
    Applicant: Pfizer Inc.
    Inventors: Brendan Murphy, Steven W. Collier, Ernest Quan, Barbara A. Johnson
  • Chewable product including active ingredient
    Patent number: 6613346
    Abstract: Products and methods of delivering medicaments are provided. The product includes a chewing gum center including a compressible powder that is compressed around the center. The powder includes a medicament that may or may not be encapsulated.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: September 2, 2003
    Assignee: Wm. Wrigley, Jr. Company
    Inventors: Donald Seielstad, Henry Tyrpin, Kevin Broderick, James Maxwell, David Record
  • Tablet obtained by direct compression comprising 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid as active ingredient
    Publication number: 20030161878
    Abstract: A tablet, obtainable by direct compression, comprising the active ingredient 4-amino-1-hydroxybutylidene-1,1-bis-phosphonic (alendronic) acid or its pharmaceutically acceptable salts in an amount of 5 to 140 mg, based on the pure acid, a dry binder, a disintegrating agent, a lubricant, the tablet comprising, as the diluent, a combination of at least two diluents except lactose.
    Type: Application
    Filed: October 24, 2002
    Publication date: August 28, 2003
    Inventor: Dagmar Jasprova
  • Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis
    Publication number: 20030161877
    Abstract: The present invention provides a pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis, which comprises 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylene dioxybiphenyl-2,2′-dicarboxylate (DDB) as major components. The ratio of oltipraz and DDB of said composition is preferably 25:0-25, more preferably 5:0.1-5, particularly preferably 5:1. Oltipraz/DDB formulations according to the present invention exhibit surprisingly good effect on the treatment and prevention of liver fibrosis and cirrhosis and are safe drugs that have low toxicity in the human body.
    Type: Application
    Filed: August 30, 2002
    Publication date: August 28, 2003
    Inventors: Sang-Geon Kim, Keon-Wook Kang
  • Method for stabilizing preparation
    Publication number: 20030161873
    Abstract: Disclosed is a method for stabilizing a solid pharmaceutical preparation containing a pharmacological substance and sodium lauryl sulfate, the method comprising incorporating into the preparation at least one member selected from the group consisting of neutral salts, basic salts and basic substances. The preparation containing sodium lauryl sulfate prepared by the method of the invention has superior performance, including high storage stability, suppression of discoloration and deterioration, and prevention of change in its properties, such as the dissolution rate of pharmacological substance from the preparation.
    Type: Application
    Filed: November 21, 2002
    Publication date: August 28, 2003
    Inventors: Yuso Tomohira, Tadashi Mukai, Minoru Kashimoto, Masakazu Nagasawa, Tetsuroh Ichiba, Daisuke Kuribayashi, Yoshikazu Oka, Hajime Toguchi
  • Tablets quickly disintegrating in mouth
    Publication number: 20030161879
    Abstract: Tablets quickly disintegrating in the mouth which comprise a bitter drug ingredient and a bitterness-reducing ingredient composed of an essential oil, a high sweetness-sweetener and/or an acidic phospholipid or its lyso-derivative. When taken even without water, these tablets exhibit little bitterness. Thus, a bitter drug ingredient can be formulated without coating into tablets quickly disintegrating in the mouth.
    Type: Application
    Filed: March 25, 2003
    Publication date: August 28, 2003
    Inventors: Shinji Ohmori, Yasuo Ohno, Tadashi Makino
  • Fast dissolving tablets of cyclooxygenase-2 enzyme inhibitors
    Publication number: 20030161875
    Abstract: The present invention relates to fast dissolving tablets for oral administration comprising a therapeutically effective amount of drug(s) that acts selectively as a cyclooxygenase-2 (COX-2) enzyme inhibitor, which disintegrate quickly in mouth. The tablets are particularly suitable for patients who have difficulty in swallowing.
    Type: Application
    Filed: February 27, 2002
    Publication date: August 28, 2003
    Inventors: Deepak Murpani, Vinod Kumar Arora, Rajiv Malik
  • Controlled release oral dosage form
    Publication number: 20030161874
    Abstract: A once a day bupropion hydrochloride formulation is disclosed.
    Type: Application
    Filed: February 8, 2002
    Publication date: August 28, 2003
    Inventors: Boyong Li, Avinash Nangia, Chih Ming Chen, Xiu Xiu Cheng
  • Granulation process and starch granulate
    Publication number: 20030161876
    Abstract: A process for the manufacture of a corn starch granulate possessing resistance to enzymatic degradation upon oral administration, comprising the steps:
    Type: Application
    Filed: March 29, 2002
    Publication date: August 28, 2003
    Inventors: Henri Hansson, Elisabeth Lindner-Olsson
  • Amoxicillin-clarithromycin antibiotic composition
    Patent number: 6610328
    Abstract: An antibiotic product for delivering at least Amoxicillin or Clarithromycin that is comprised of three dosage forms with different release profiles with each of Amoxicillin and Clarithromycin being present in at least one of the dosage forms.
    Type: Grant
    Filed: March 7, 2002
    Date of Patent: August 26, 2003
    Assignee: Advancis Pharmaceutical Corp.
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
  • Tablets to be crunched or sucked, comprising iron as active principle
    Patent number: 6610325
    Abstract: This pharmaceutical medicine comprises an iron salt, not less than two polyols, a binding agent, a lubricating agent, and a flavoring agent. The dose of elemental iron is not less than 5 mg, and preferably 10 mg to 15 mg per tablet. The proportion of one of the polyols on its own is not less than 10%, and preferably not less than 20% of the total mass of the tablet, the overall proportion of the polyols being not less than 50% and preferably not less than 75%. One of the two polyols is xylitol, comprising not less than 10%, and preferably not less than 20%. The other polyol is sorbitol and/or mannitol.
    Type: Grant
    Filed: October 23, 2000
    Date of Patent: August 26, 2003
    Assignee: Laboratoire Innothera
    Inventors: Catherine Meignant, Stephanie Verdier
  • Divalproex sodium tablets
    Patent number: 6610326
    Abstract: A process for preparing divalproex sodium tablets is provided. The process comprises preparing a neutralized divalproex sodium solution by combining divalproex sodium, having a sodium valproate and a valproic acid moiety, with an aqueous solvent and a base, e.g., sodium hydroxide, the base being in sufficient amount to ensure neutralization of the valproic acid moiety of the divalproex sodium. The neutralized divalproex sodium solution is sprayed onto a pharmaceutically acceptable carrier, and processed to obtain divalproex sodium tablets.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: August 26, 2003
    Assignee: Andrx Corporation
    Inventors: Chih-Ming Chen, Boyong Li
  • Pharmaceutical moxifloxacin preparation
    Patent number: 6610327
    Abstract: The present invention relates to a pharmaceutical preparation for oral administration which comprises moxifloxacin, its salt and/or hydrate and lactose, to a process for its preparation, and to the use of this preparation for controlling bacterial infections in humans and animals.
    Type: Grant
    Filed: April 30, 2001
    Date of Patent: August 26, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Patrick Bosché, Hans Friedrich Mahler, Claus Weisemann